Skip to main content
SVBI logo

SVBI — Investor Relations & Filings

Ticker · 1786 ISIN · TW0001786002 TW Manufacturing
Open in API
Filings indexed 1,687 across all filing types
Latest filing 2022-11-04 Audit Report / Informat…
Country TW Taiwan
Listing TW 1786

About SVBI

www.scivision.com.tw

SciVision Biotech Inc. is a specialized developer and manufacturer of advanced medical devices, focusing on the research and production of hyaluronic acid (HA) products. The company leverages its proprietary Crosslinked Hyaluronic Acid Platform (CHAP) technology to create high-performance solutions across multiple medical disciplines. Its core product portfolio includes subcutaneous fillers for facial aesthetics, intra-articular injections for orthopedic joint care, anti-adhesion gels for surgical applications, and vesical instillation solutions for urological treatments. By integrating specialized R&D capabilities with precision manufacturing, SciVision Biotech provides medical-grade HA applications designed to improve patient outcomes in aesthetics and therapeutic recovery. The company is committed to scientific innovation and the expansion of its patented technology to meet diverse clinical needs in the global healthcare market.

Recent filings

Filing Released Lang Actions
111年第3季財務報告書 — 202204_1786_AIA.pdf
Audit Report / Information Classification · 100% confidence The document is titled 'Consolidated Financial Statements and Independent Auditors' Report For the Years Ended December 31, 2022 and 2021' and contains detailed audit opinion, basis for audit opinion, key audit matters, responsibilities of management and auditors, and consolidated financial statements including balance sheets. The content is a full audit report with financial statements and notes, not just an announcement or certification. It is a standalone audit report covering the audit of the consolidated financial statements for the fiscal years ended December 31, 2022 and 2021. Therefore, it fits the category of Audit Report / Information (AR). FY 2022
2022-11-04 Chinese
111年第3季財務報告書 — 202204_1786_AI3.pdf
Regulatory Filings
2022-11-04 Chinese
111年第3季財務報告書 — 202204_1786_AI1.pdf
Regulatory Filings
2022-11-04 Chinese
111年第3季財務報告書 — 202203_1786_AI1.pdf
Regulatory Filings
2022-11-04 Chinese
111年第3季財務報告書 — 202202_1786_AI1.pdf
Regulatory Filings
2022-11-04 Chinese
111年第3季財務報告書 — 202201_1786_AI1.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "合併財務報告暨會計師核閱報告" which translates to "Consolidated Financial Report and Accountant's Review Report". It covers the period from January 1 to March 31 of 民國一一一年 (Year 111 in the ROC calendar, corresponding to 2022) and the previous year. The content includes consolidated balance sheets, income statements, cash flow statements, notes to financial statements, and an accountant's review report. The document is about 15,000 characters long, indicating it is a full financial report rather than a brief announcement or certification. The presence of detailed financial statements and notes confirms it is an interim or quarterly financial report. The accountant's review report (核閱報告) is typical for interim financial statements rather than a full audit report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2022
2022-11-04 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.